Skip to main content
. 2010 Feb 19;5(2):e9313. doi: 10.1371/journal.pone.0009313

Figure 2. Immunohistochemical analysis of the autophagy pathway in the brains of AD and DLB patients.

Figure 2

Vibratome sections from the temporal cortex of non-demented controls, AD, and DLB patients were immunolabeled with antibodies against mTor, Atg7, Cathepsin D, and LC3, and imaged with a digital microscope. (A–C) Representative sections from control, AD and DLB brains immunolabeled with an antibody against mTor. (D–F) Representative sections from control, AD and DLB brains immunolabeled with an antibody against Atg7. (G) Semi-quantitative image analysis reveals a significant increase in mTor levels and a reduction in Atg7 levels in DLB patients compared to controls. (H–J) Representative sections from control, AD and DLB brains immunolabeled with an antibody against Cathepsin D. Pyramidal neurons in AD and DLB cases show enlarged Cathepsin D-immunoreactive lysosomes (arrows). (K–M) Representative sections from control, AD and DLB brains immunolabeled with an antibody against LC3. (N) Increased numbers of enlarged lysosomes (>1µm) in AD and DLB brains. (O) Semi-quantitative image analysis of LC3 immunoreactivity reveals increased LC3 levels in AD and DLB brains. Scale bar in panel (C) represents 20µm in all microscopy images. *p<0.05 compared to non-demented controls by one-way ANOVA with post-hoc Dunnett's test.